CDKN2A and cancer: Strong p16 staining was linked to shortened overall survival if all cancers were jointly analyzed (p = 0.0038, Figure 2A), as well as in the subsets of NST cancers (p = 0.0048, Figure 2B), and in the subset of cancers with nodal metastases (p < 0.0001, Figure 2D).